Amigo, an AI platform dedicated to creating safe and reliable clinical agents for healthcare organizations, has announced the creation of its Medical Advisory Board with the appointment of Dr. Jay Shah, MD as Chief Medical Advisor. Dr. Shah, who serves as Chief of the Medical Staff at Stanford Health Care, will oversee Amigo’s clinical strategy and help ensure that the platform adheres to rigorous healthcare standards. As the first member of the advisory board, he will collaborate closely with Amigo’s leadership team to guide product development, establish frameworks for clinical validation, and make sure the platform addresses practical challenges faced by healthcare providers.
Health Technology Insights: Wolters Kluwer Launches Ovid Synthesis Expert AI
Ali Khokhar, CEO of Amigo, emphasized that understanding clinical care is essential for responsibly implementing AI in healthcare. He said that Dr. Shah’s perspective as a practicing physician will be critical in designing a new approach to clinical AI and that his guidance will help Amigo scale clinical expertise responsibly.
Health Technology Insights: Hippocratic AI Selects Fivetran to Power Trusted Data Infrastructure for AI in Healthcare
Dr. Shah is a cancer surgeon and associate professor of Urology at Stanford University School of Medicine. He is widely recognized for his expertise in robotic surgery and the treatment of bladder cancer. Before his role at Stanford, he served as Center Medical Director at the Genitourinary Center at MD Anderson Cancer Center, where he launched the bladder cancer robotics program and developed an enhanced recovery pathway for patients undergoing bladder removal surgery.
Dr. Shah earned his undergraduate degree from Harvard College and completed his medical degree and residency at Columbia University. During his training, he was elected to the Alpha Omega Alpha Medical Honor Society, recognized as Physician of the Year, and awarded the Gold Foundation Excellence in Teaching Award. He highlighted the importance of combining AI with clinical insight and safeguards and said he joined Amigo because the company is building its solutions with transparency and clinical rigor, which he believes can transform patient care.
Amigo’s Medical Advisory Board will bring together clinical leaders from various disciplines to provide ongoing guidance on the company’s product roadmap, ensuring that the AI platform meets healthcare’s complex regulatory, operational, and patient care requirements while advancing safe and effective clinical solutions.
Health Technology Insights: Cardiosense Shows AI Heart Failure Data at Transcatheter Cardiovascular Therapeutics 2025
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
